ArticleFrontiers in medicine2025
Case Report: JAK inhibitors for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis with spontaneous pneumomediastinum.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Spontaneous pneumomediastinum (SPNM) occurred more frequently in dermatomyositis (DM) patients with anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibody than in DM patients without anti-MDA5 antibody. SPNM has been indicated as a risk factor for death in anti-MDA5-positive DM. There have been no clinical studies evaluating the treatment strategy for SPNM in anti-MDA5-positive DM. Methods: We present a series of five cases in which the administration of Janus kinase (JAK) inhibitors improved the clinical condition of anti-MDA5-positive DM patients with SPNM. Results: Clinical conditions of the four patients who were given JAK inhibitors after the diagnosis of SPNM were all improved. SPNM symptoms of the patient who was not commenced on JAK inhibitors progressed, and the patient died of severe pulmonary infection. Conclusion: JAK inhibitors appear to be an efficient therapeutic option in the treatment of anti-MDA5-positive DM with SPNM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.